Condition
Primary CNS Lymphoma (PCNSL)
Total Trials
5
Recruiting
3
Active
3
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
5Total
P 2 (4)
P 4 (1)
Trial Status
Recruiting3
Completed1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06931652Phase 2RecruitingPrimary
Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab
NCT07062627Phase 2RecruitingPrimary
Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma
NCT06737250Phase 2RecruitingPrimary
NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL
NCT05274139Phase 2CompletedPrimary
Treatment of Primary CNS Lymphoma ( FTD )
NCT01960192Phase 4UnknownPrimary
Treatment of Primary CNS Lymphoma
Showing all 5 trials